All Stories

  1. The efficacy and safety of olaparib in the treatment of cancers: a meta-analysis of randomized controlled trials

    Article • Cancer Management and Research, August 2018, Dove Medical Press

    Mr xi zhang

  2. Risk of severe hematologic toxicities in cancer patients treated with PARP inhibitors: a meta-analysis of randomized controlled trials

    Article • Drug Design Development and Therapy, October 2017, Dove Medical Press

    Mr xi zhang

  3. Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis

    Article • Drug Design Development and Therapy, September 2016, Dove Medical Press

    Mr xi zhang

  4. Incidence and risk of severe infections associated with aflibercept in cancer patients: a systematic review and meta-analysis

    Article • British Journal of Clinical Pharmacology, October 2015, Wiley

    Mr xi zhang